Application of 2019-nCoV3CL hydrolase inhibitor and IL-6 monoclonal antibody in preparation of treatment novel coronavirus pneumonia drug

A 2019-ncov3cl and inhibitor technology, applied in the field of medicine, can solve problems such as difficulty in completing the formation of autoantibodies

Inactive Publication Date: 2020-04-24
NANTONG UNIVERSITY
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In response to autoimmune attacks on lung tissue, hormones (such as glucocorticoids) are used to suppress immunity to avoid further lung tissue damage, but at the same time suppress the immune response, m

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 2019-nCoV3CL hydrolase inhibitor and IL-6 monoclonal antibody in preparation of treatment novel coronavirus pneumonia drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] 2019-nCoV is also a positive strand virus (Positive stranded RNA virus) like the SARS-CoV virus that belongs to the severe acute respiratory syndrome-related coronavirus species. Translate to form a polyprotein (polyprotein), which mainly performs virus replication and transcription, but to function, it must be transformed into some polypeptides (polypeptides) with certain biochemical functions through protein dissolution (Proteolytic processing). This step works It is done by protease (Proteinase). Therefore, 3CL proteolytic enzyme (3CL Mpro) is considered as an ideal target for anti-SARS-CoV drug screening. The corresponding enzyme is also considered as a potential target of 2019-nCoV. For the high-resolution crystal structure of the 2019-nCoV hydrolase (Mpro) of the new coronavirus that has been obtained, the strategy of combining virtual screening and enzymatic testing can be used comprehensively, as well as four databases including BindingDB, PubChem, ChEMBL and P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a 2019-nCoV3CL hydrolase (Mpro) inhibitor and an interleukin-6 (IL-6) monoclonal antibody in preparation of a treatment novel coronavirus pneumonia drug, and belongs to the technical field of medicines. Through establishing a Vero E6 cell and macrophage Thp-1 co-culture model inoculated with novel coronavirus virus 2019-nCoV, and simulating a process of generating inflammatory response by novel coronavirus virus in a cell body; the combined application of the inhibitor aiming at 2019-nCoV Mpro and the monoclonal antibody for reversing macrophage M1 type pro-inflammatory polarization is designed, and the result shows that the combined application of the inhibitor and the monoclonal antibody is beneficial to cure and prognosis recovery of novel coronavirus pneumonia.

Description

technical field [0001] The invention belongs to the field of medical technology, and specifically relates to the application of 2019-nCoV3CL hydrolase (Mpro) inhibitors and interleukin-6 (IL-6) monoclonal antibodies in the preparation of drugs for the treatment of new coronary pneumonia. Background technique [0002] It is currently known that 2019-nCoV3CL hydrolase is involved in the replication of the new coronavirus in the human body, and the purpose of treating new coronary pneumonia can be achieved by inhibiting the action of this hydrolase. However, due to the stimulation of the virus in patients with COVID-19, the M1 type of macrophages is overactivated and secretes excessive pro-inflammatory factors and chemokines, while the activation of M2 type macrophages is inhibited, resulting in the failure of repair of inflammatory damaged tissues. Form a positive feedback loop, and then break through the threshold and get out of control, and finally form a cytokine storm, lea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K39/395A61K38/08A61K31/4725A61P31/14
CPCA61K31/4725A61K38/08A61K39/3955A61K45/06A61P31/14A61K2300/00
Inventor 王国华周佳敏叶莉莎孙叶超姜正林李霞骆倩倩徐丽华
Owner NANTONG UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap